Okla. Firefighters Pension & Ret. Sys. v. Nektar Therapeutics (In re Nektar Therapeutics Sec. Litig.), 34 F.4th 828 (U.S. 9th Cir. 2022)
This decision affirms dismissal of a 10b-5 securities complaint, holding that the complaint did not adequately allege falsity or loss causation. The alleged omission concerned the results of a stage 1 drug trial for a cancer treatment drug. Nektar reported that the drug increased cancer-fighting T cells by 30 times in the stage one test group of 10 patients. Plaintiffs… Read More